Adawi Kamal sold $14K of FATE
Adawi Kamal (Chief Financial Officer) sold 6,582 shares of FATE THERAPEUTICS INC (FATE) at $2.05 on 2026-11-03.
How this was made
The 30-second read
Why it matters
The disclosed sale is modest and unlikely to move the stock significantly, but adds to the flow of insider activity data.
Market read
Small insider sell; minimal immediate trading impact.
What to watch
No 10b5-1 plan; CFO may be diversifying holdings.
Background
Form 4 filing discloses insider transactions; investors monitor CFO sales for signals.
Ticker impact
CFO Adawi Kamal sold 6,582 shares for $13.5K, reducing his stake to 93,418 shares.
likely modest pressure as the market prices in the insider sale.
The sale is small relative to total holdings and market cap, but CFO insider activity is watched by traders.
Market effects
Limited impact on biotech sector; typical insider sale.
None
None
Counterpoint
The sale could be routine portfolio rebalancing, not a red flag.
Key entities
- CompanyFate Therapeutics Inc.
Biotech firm developing cellular immunotherapies.
- PersonAdawi Kamal
Chief Financial Officer of Fate Therapeutics.